Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fondaparinux Sodium

FDA-approved product (solution, subcutaneous), marketed as Arixtra, Fondaparinux Sodium.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Fondaparinux Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Deep vein thrombosis
  • Intermediate coronary syndrome
  • Myocardial infarction
  • Pulmonary embolism
  • Recurrent thrombophlebitis
  • Venous thrombosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antithrombotic agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae42.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fondaparinux Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fondaparinux Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis

    NCT00789399 · start 2009-11-19

    Registered record
    Registry ID
    NCT00789399
    Conditions
    Deep Vein Thrombosis; Coronary Artery Bypass Surgery; Venous Thromboembolism
    Interventions
    Fondaparinux; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2009-11-19
    Completion
    2013-09-21
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDeep Vein Thrombosis; Coronary Artery Bypass Surgery; Venous Thromboembolism
    InterventionFondaparinux; Placebo
    PhaseNot applicable
    Registry statusTerminated

  • Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General Surgery

    NCT01390896 · start 2009-09

    Registered record
    Registry ID
    NCT01390896
    Conditions
    Cardiovascular Disease
    Interventions
    Fondaparinux Sodium
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-09
    Completion
    2013-01
    Enrolment
    329

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Disease
    InterventionFondaparinux Sodium
    PhaseNot recorded
    Registry statusCompleted

  • Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients

    NCT00894283 · start 2009-06

    Registered record
    Registry ID
    NCT00894283
    Conditions
    Deep Venous Thrombosis; Pulmonary Embolism
    Interventions
    Enoxaparin; Fondaparinux
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2009-06
    Completion
    2013-09
    Enrolment
    198

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDeep Venous Thrombosis; Pulmonary Embolism
    InterventionEnoxaparin; Fondaparinux
    PhaseEarly phase 1
    Registry statusCompleted

  • Prophylaxis of Thromboembolic Complications Trial: Thromboprophylaxis Needed in Below Knee Plaster Cast Immobilization for Ankle and Foot Fractures

    NCT00881088 · start 2009-04

    Registered record
    Registry ID
    NCT00881088
    Conditions
    Deep Vein Thrombosis; Pulmonary Embolism
    Interventions
    Nadroparin; Fondaparinux
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2009-04
    Completion
    2013-04
    Enrolment
    669

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDeep Vein Thrombosis; Pulmonary Embolism
    InterventionNadroparin; Fondaparinux
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)

    NCT00790907 · start 2009-02

    Registered record
    Registry ID
    NCT00790907
    Conditions
    Acute Coronary Syndrome
    Interventions
    fondaparinux background and standard dose UFH; Fondaparinux background and low dose heparin; Open label fondaparinux
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-02
    Completion
    2010-05
    Enrolment
    3,235

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome
    Interventionfondaparinux background and standard dose UFH; Fondaparinux background and low dose heparin; Open label fondaparinux
    PhasePhase 4
    Registry statusCompleted

  • Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal (Urology,Obstetrics,Gynecology)

    NCT01390883 · start 2008-12

    Registered record
    Registry ID
    NCT01390883
    Conditions
    Cardiovascular Disease
    Interventions
    Fondaparinux Sodium
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-12
    Completion
    2013-10
    Enrolment
    475

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Disease
    InterventionFondaparinux Sodium
    PhaseNot recorded
    Registry statusCompleted

  • Fondaparinux EU-RMP (Adherence)

    NCT01406301 · start 2008-03

    Registered record
    Registry ID
    NCT01406301
    Conditions
    Acute Coronary Syndrome
    Interventions
    fondaparinux
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-03
    Completion
    2011-07
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome
    Interventionfondaparinux
    PhaseNot recorded
    Registry statusCompleted

  • Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)

    NCT00603824 · start 2008-01

    Registered record
    Registry ID
    NCT00603824
    Conditions
    Heparin-Induced Thrombocytopenia
    Interventions
    fondaparinux; argatroban or lepirudin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2008-01
    Completion
    2010-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeparin-Induced Thrombocytopenia
    Interventionfondaparinux; argatroban or lepirudin
    PhasePhase 4
    Registry statusWithdrawn

  • Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression

    NCT00659399 · start 2008-01

    Registered record
    Registry ID
    NCT00659399
    Conditions
    Ovarian Carcinoma
    Interventions
    Fondaparinux
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2008-01
    Completion
    2010-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Carcinoma
    InterventionFondaparinux
    PhasePhase 1
    Registry statusWithdrawn

  • Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

    NCT00673439 · start 2007-11

    Registered record
    Registry ID
    NCT00673439
    Conditions
    Heparin-Induced Thrombocytopenia
    Interventions
    fondaparinux; warfarin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2007-11
    Completion
    2011-09
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeparin-Induced Thrombocytopenia
    Interventionfondaparinux; warfarin
    PhasePhase 2
    Registry statusTerminated

  • Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer

    NCT00476216 · start 2007-09

    Registered record
    Registry ID
    NCT00476216
    Conditions
    Non-Small Cell Lung Cancer; Venous Thromboembolism
    Interventions
    Combination of Arixtra with chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-09
    Completion
    2013-12
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer; Venous Thromboembolism
    InterventionCombination of Arixtra with chemotherapy
    PhasePhase 1
    Registry statusCompleted

  • Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection

    NCT01420809 · start 2007-09

    Registered record
    Registry ID
    NCT01420809
    Conditions
    Thromboembolism
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-09
    Completion
    2009-08
    Enrolment
    1,280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThromboembolism
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Pharmacokinetic Study of Fondaparinux in Outpatients With Renal Dysfunction

    NCT00483600 · start 2007-08

    Registered record
    Registry ID
    NCT00483600
    Conditions
    Kidney Diseases
    Interventions
    fondaparinux
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2007-08
    Completion
    2008-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Diseases
    Interventionfondaparinux
    PhaseNot applicable
    Registry statusWithdrawn

  • Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients

    NCT00493896 · start 2007-07

    Registered record
    Registry ID
    NCT00493896
    Conditions
    Venous Thromboembolism
    Interventions
    Fondaparinux; Enoxaparin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2007-07
    Completion
    2010-04
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboembolism
    InterventionFondaparinux; Enoxaparin
    PhasePhase 3
    Registry statusTerminated

  • The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients

    NCT00981409 · start 2007-07

    Registered record
    Registry ID
    NCT00981409
    Conditions
    Embolism, Pulmonary
    Interventions
    Fondaparinux sodium; unfractionated heparin (UFH)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-07
    Completion
    2008-12
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEmbolism, Pulmonary
    InterventionFondaparinux sodium; unfractionated heparin (UFH)
    PhasePhase 3
    Registry statusCompleted